Hydroxychloroquine barely beats placebo in COVID-19, but research goes on

4 June 2020

coronavirus_credit_deposit_photos-_largre

The latest study on hydroxychloroquine – a drug that US President Donald Trump boasted about taking – has shown that it was barely better than placebo at preventing COVID-19.

An article on the 821-patient trial was published on Wednesday in the New England Journal of Medicine (NEJM), revealing that there was no significant difference in the outcomes between the placebo and hydroxychloroquine patients, who had household or occupational exposure to someone with confirmed Covid-19.

Side effects higher, but none serious

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK